Peter Lachman

Peter Lachman is a seasoned professional in business development and investment banking, currently serving in a Business Development and M&A role at Sarepta Therapeutics since August 2022. Prior experience includes notable positions at Leerink Partners and SAIGroup, where a focus was placed on the biopharma sector and private investments in AI-enabled businesses. Lachman's earlier roles include Business Development/M&A at Horizon and Vice President at Corporate Fuel Partners, contributing to middle market private equity initiatives. Educational credentials feature a Master's of Business Administration from NYU Stern School of Business, an MPhil from the University of Cambridge, and a BA in International Political Economy from Fordham University. Key achievements include participation in significant transactions such as the $2.6 billion sale of Auxilium Pharmaceuticals and the IPOs of Diplomat Pharmacy and Ocular Therapeutix. Additionally, Lachman has served as a Board Observer for various organizations, including EnergyWatch and Genisphere.